Filing Flows › Vir Biotechnology (VIR) › Q3 2025
Vir Biotechnology (VIR) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Vir Biotechnology (VIR) reported revenue of $240K for the third quarter 2025 (Q3 2025), -90% from a year earlier and -80% from the quarter before.
Vir Biotechnology, Q3 2025: revenue $240K (-90% year over year), net loss $163M, operating cash flow −$168M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $240K | -80% | -90% |
| Operating profit | −$173M | — | — |
| Net earnings | −$163M | — | — |
| Operating cash flow | −$168M | — | — |
What changed
Revenue was $240K in Q3 2025, down 90% year over year and down 80% from the previous quarter.
Operating costs exceeded revenue by $173.4M, an operating margin of -72267.9%. Total costs fell 26% while revenue fell 90%. The quarter ended with a net loss of $163.1M, wider than the previous quarter's $111.0M loss.
Operating cash flow was −$167.6M. Non-cash charges added back $3.0M of depreciation and amortization and $11.4M of share-based compensation. Working capital and other items used $18.8M. Capital expenditures of $317K exceeded it, leaving free cash flow of −$167.9M.
Questions
What was Vir Biotechnology's revenue in the third quarter 2025?
Vir Biotechnology (VIR) reported revenue of $240K for the third quarter 2025 (Q3 2025), -90% from a year earlier and -80% from the quarter before.
Source: Vir Biotechnology 10-Q on SEC EDGAR.